What Will Happen to ADMA Biologics, Inc. (ADMA) Next? The Stock Just Declined A Lot

ADMA Biologics, Inc. (NASDAQ:ADMA) Logo

Investors sentiment increased to 4.56 in 2019 Q2. Its up 3.25, from 1.31 in 2019Q1. It increased, as 3 investors sold ADMA Biologics, Inc. shares while 6 reduced holdings. 12 funds opened positions while 29 raised stakes. 63.95 million shares or 192.43% more from 21.87 million shares in 2019Q1 were reported.
Ontario – Canada-based Savings Bank Of Montreal Can has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Northern holds 299,248 shares or 0% of its portfolio. Perceptive Advisors Limited Com owns 11.52M shares. Vanguard Grp Inc reported 0% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA). Financial Architects holds 0.01% or 19,500 shares. Blackrock stated it has 1.90 million shares or 0% of all its holdings. Private Advisor Group Ltd Liability Com, a New Jersey-based fund reported 17,545 shares. Geode Cap Limited Liability Company invested in 0% or 437,560 shares. Raymond James & Associate holds 49,251 shares or 0% of its portfolio. Alyeska Gru Limited Partnership reported 0.03% in ADMA Biologics, Inc. (NASDAQ:ADMA). Meeder Asset invested in 0% or 1,289 shares. Royal Fincl Bank Of Canada has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Utd Service Automobile Association stated it has 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Deutsche Bank Ag holds 0% or 36,171 shares in its portfolio. Citigroup Incorporated invested in 7,595 shares.

Since May 17, 2019, it had 6 insider buys, and 1 sale for $5.50 million activity. Grossman Jerrold B bought $48,000 worth of stock. Guiheen Lawrence P. bought $100,000 worth of stock. The insider Grossman Adam S bought $120,000. 5,000 ADMA Biologics, Inc. (NASDAQ:ADMA) shares with value of $20,000 were bought by LENZ BRIAN. PERCEPTIVE ADVISORS LLC bought $16.00 million worth of stock or 4.00 million shares. Mond James had bought 4,500 shares worth $18,000 on Friday, May 17.

The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) is a huge mover today! The stock decreased 2.01% or $0.11 during the last trading session, reaching $5.11. About 541,726 shares traded. ADMA Biologics, Inc. (NASDAQ:ADMA) has declined 42.36% since September 13, 2018 and is downtrending. It has underperformed by 42.36% the S&P500.
The move comes after 5 months negative chart setup for the $303.41 million company. It was reported on Sep, 13 by Barchart.com. We have $4.75 PT which if reached, will make NASDAQ:ADMA worth $21.24M less.

Analysts await ADMA Biologics, Inc. (NASDAQ:ADMA) to report earnings on November, 14. They expect $-0.21 EPS, up 36.36 % or $0.12 from last year’s $-0.33 per share. After $-0.25 actual EPS reported by ADMA Biologics, Inc. for the previous quarter, Wall Street now forecasts -16.00 % EPS growth.

ADMA Biologics, Inc. (NASDAQ:ADMA) Ratings Coverage

Among 5 analysts covering ADMA Biologics (NASDAQ:ADMA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ADMA Biologics has $16 highest and $800 lowest target. $10.90’s average target is 113.31% above currents $5.11 stock price. ADMA Biologics had 8 analyst reports since March 14, 2019 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Thursday, March 14. Oppenheimer maintained the stock with “Outperform” rating in Tuesday, April 2 report. The company was maintained on Thursday, March 14 by H.C. Wainwright. The rating was maintained by Chardan Capital Markets on Thursday, March 14 with “Buy”.

More notable recent ADMA Biologics, Inc. (NASDAQ:ADMA) news were published by: Seekingalpha.com which released: “ADMA Bio closes $52M capital raise – Seeking Alpha” on May 21, 2019, also Globenewswire.com with their article: “ADMA Biologics Announces Pricing of Public Offering of Common Stock – GlobeNewswire” published on May 17, 2019, Globenewswire.com published: “FDA Approves ASCENIVâ„¢, a Novel Intravenous Immune Globulin – GlobeNewswire” on April 01, 2019. More interesting news about ADMA Biologics, Inc. (NASDAQ:ADMA) were released by: Nasdaq.com and their article: “Here’s Why ADMA Biologics Is Getting Hammered Today – Nasdaq” published on December 20, 2018 as well as Seekingalpha.com‘s news article titled: “ADMA: Ready To Capitalize On The IVIG Shortage – Seeking Alpha” with publication date: September 03, 2019.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, makes, and intends to commercialize specialty plasma biologics for the treatment and prevention of immune deficiencies and infectious diseases. The company has market cap of $303.41 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.